1. Home
  2. GTBP vs CHEK Comparison

GTBP vs CHEK Comparison

Compare GTBP & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GTBP
  • CHEK
  • Stock Information
  • Founded
  • GTBP 1965
  • CHEK 2004
  • Country
  • GTBP United States
  • CHEK Israel
  • Employees
  • GTBP N/A
  • CHEK N/A
  • Industry
  • GTBP Biotechnology: Pharmaceutical Preparations
  • CHEK Medical Electronics
  • Sector
  • GTBP Health Care
  • CHEK Health Care
  • Exchange
  • GTBP Nasdaq
  • CHEK Nasdaq
  • Market Cap
  • GTBP 5.6M
  • CHEK 4.5M
  • IPO Year
  • GTBP N/A
  • CHEK 2015
  • Fundamental
  • Price
  • GTBP $2.36
  • CHEK $0.81
  • Analyst Decision
  • GTBP Strong Buy
  • CHEK
  • Analyst Count
  • GTBP 1
  • CHEK 0
  • Target Price
  • GTBP $11.00
  • CHEK N/A
  • AVG Volume (30 Days)
  • GTBP 33.2K
  • CHEK 52.9K
  • Earning Date
  • GTBP 05-14-2025
  • CHEK 05-14-2025
  • Dividend Yield
  • GTBP N/A
  • CHEK N/A
  • EPS Growth
  • GTBP N/A
  • CHEK N/A
  • EPS
  • GTBP N/A
  • CHEK N/A
  • Revenue
  • GTBP N/A
  • CHEK N/A
  • Revenue This Year
  • GTBP N/A
  • CHEK N/A
  • Revenue Next Year
  • GTBP N/A
  • CHEK N/A
  • P/E Ratio
  • GTBP N/A
  • CHEK N/A
  • Revenue Growth
  • GTBP N/A
  • CHEK N/A
  • 52 Week Low
  • GTBP $1.72
  • CHEK $0.56
  • 52 Week High
  • GTBP $10.66
  • CHEK $3.04
  • Technical
  • Relative Strength Index (RSI)
  • GTBP 50.10
  • CHEK 47.11
  • Support Level
  • GTBP $2.10
  • CHEK $0.77
  • Resistance Level
  • GTBP $2.45
  • CHEK $0.86
  • Average True Range (ATR)
  • GTBP 0.18
  • CHEK 0.08
  • MACD
  • GTBP -0.01
  • CHEK 0.00
  • Stochastic Oscillator
  • GTBP 56.43
  • CHEK 41.46

About GTBP GT Biopharma Inc.

GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

About CHEK Check-Cap Ltd.

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: